» Articles » PMID: 10207464

Small Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation Versus Ethanol Injection

Overview
Journal Radiology
Specialty Radiology
Date 1999 Apr 20
PMID 10207464
Citations 235
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To compare the effectiveness of radio-frequency (RF) ablation with that of percutaneous ethanol injection in the treatment of small hepatocellular carcinoma (HCC).

Materials And Methods: Eighty-six patients with 112 small (< or = 3-cm-diameter) HCCs underwent RF ablation (42 patients with 52 tumors) or percutaneous ethanol injection (44 patients with 60 tumors). Therapeutic efficacy was evaluated with dual-phase spiral computed tomography performed at least 4 months after treatment.

Results: Complete necrosis was achieved in 47 of 52 tumors with RF ablation (90%) and in 48 of 60 tumors with percutaneous ethanol injection (80%). These results were obtained with an average of 1.2 sessions per tumor with RF ablation and 4.8 sessions per tumor with percutaneous ethanol injection. One major complication (hemothorax that required drainage) and four minor complications (intraperitoneal bleeding, hemobilia, pleural effusion, cholecystitis) occurred in patients treated with RF ablation; no complications occurred in patients treated with percutaneous ethanol injection.

Conclusion: RF ablation results in a higher rate of complete necrosis and requires fewer treatment sessions than percutaneous ethanol injection. However, the complication rate is higher with RF ablation than with percutaneous ethanol injection. RF ablation is the treatment of choice for most patients with HCC.

Citing Articles

The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors.

Mendiratta-Lala M, Wiggermann P, Pech M, Serres-Creixams X, White S, Davis C Radiology. 2024; 312(3):e233051.

PMID: 39225612 PMC: 11427859. DOI: 10.1148/radiol.233051.


Machine Learning-Based Personalized Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation.

Sato M, Tateishi R, Moriyama M, Fukumoto T, Yamada T, Nakagomi R Gastro Hep Adv. 2024; 1(1):29-37.

PMID: 39129938 PMC: 11308827. DOI: 10.1016/j.gastha.2021.09.003.


A history of the treatment of primary liver cancer.

Bruix J Clin Liver Dis (Hoboken). 2024; 23(1):e0147.

PMID: 38707239 PMC: 11068144. DOI: 10.1097/CLD.0000000000000147.


Determining the Relationship between Delivery Parameters and Ablation Distribution for Novel Gel Ethanol Percutaneous Therapy in Ex Vivo Swine Liver.

Chelales E, von Windheim K, Banipal A, Siebeneck E, Benham C, Nief C Polymers (Basel). 2024; 16(7).

PMID: 38611255 PMC: 11013462. DOI: 10.3390/polym16070997.


Factors Impacting Microwave Ablation Zone Sizes: A Retrospective Analysis.

Mathy R, Giannakis A, Franke M, Winiger A, Kauczor H, Chang D Cancers (Basel). 2024; 16(7).

PMID: 38610957 PMC: 11011160. DOI: 10.3390/cancers16071279.